• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20330 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2007     Haute Autorite de sante (HAS) Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2006     Agency for Healthcare Research and Quality (AHRQ) Value of the periodic health evaluation
2011     Agency for Healthcare Research and Quality (AHRQ) Values of older adults related to primary and secondary prevention
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2007     National Institute for Health and Clinical Excellence (NICE) Varenicline for smoking cessation
2009     Center for Evidence-based Practice (CEP) Varenicline for smoking cessation
2007     Quality Improvement Scotland (NHS QIS ) Varenicline for smoking cessation
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2009     NIHR Health Technology Assessment programme Varenicline in the management of smoking cessation: a single technology appraisal
2001     Health Council of the Netherlands Gezondheidsraad (GR) Variant Creutzfeldt-Jakob disease and blood transfusion - review, expert panel
2014     NIHR Health Services and Delivery Research programme Variation in compulsory psychiatric inpatient admission in England: a cross-sectional, multilevel analysis
2017     NIHR Health Services and Delivery Research programme Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2014     NIHR Health Services and Delivery Research programme Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec - nonsystematic review
1993     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in the frequency of surgical procedures by region in the province of Quebec - nonsystematic review
2020     NIHR Health Services and Delivery Research programme Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2014     New Zealand National Health Committee (NHC) Varicella and rotovirus vaccination in New Zealand - assessment reports
2000     University HealthSystem Consortium (UHC) Varicella-zoster
2004     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Vascular bipolar electrocoagulation (LigaSure (TM)) and Tissular electrocoagulation and section (TissueLink (TM)) - preliminary report
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
1989     The Swedish Council on Health Technology Assessment (SBU) Vascular surgery for arteriosclerosis in the legs
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
2013     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review
2015     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review (update)
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Vasopressin as first-line therapy for cardiac arrest: a review of the guidelines and clinical-effectiveness
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2003     Centre for Clinical Effectiveness (CCE) Vasospasm following subarachnoid haemorrhage: papaverine infusion, nimodipine infusion or balloon angioplasty?
2005     Adelaide Health Technology Assessment (AHTA) Vasotrac (R) continuous blood pressure monitoring
2009     HAYES, Inc. VasoView HemoPro endoscopic vein harvesting system (Maquet Cardiovascular LLC) for coronary artery bypass graft (CABG)
2012     NIHR Horizon Scanning Centre (NIHR HSC) VBLOC® vagal blocking therapy for obesity
2021     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for Crohn's disease – second or subsequent line
2014     NIHR Health Technology Assessment programme Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for ulcerative colitis – second or subsequent line
2011     NIHR Horizon Scanning Centre (NIHR HSC) VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
1998     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Vein-graft surveillance - primary research
2012     HAYES, Inc. VeinViewer (Christie Digital Systems USA Inc.) for guiding venous access procedures in children
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Velaglucerase alfa
2009     NIHR Horizon Scanning Centre (NIHR HSC) Velaglucerase alfa for type 1 Gaucher's disease
2010     HAYES, Inc. Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Velcalcetide for secondary hyperparathyroidism – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2016     NIHR Horizon Scanning Centre (NIHR HSC) Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy
2010     Adelaide Health Technology Assessment (AHTA) Velscope for oral cancer screening
2008     Adelaide Health Technology Assessment (AHTA) Velscope(R) for oral cancer screening
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib (Zelboraf) for metastatic BRAF V600 mutation positive melanoma in children and adolescents
2014     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma
2012     NIHR Health Technology Assessment programme Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
2015     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax for chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
2016     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line
2021     NIHR Health Technology Assessment programme Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2021     Center for Evidence-based Practice (CEP) Venous irritation resulting from IV fosaprepitant
2018     Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2009     Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for bariatric surgery
2007     Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for hip fracture patients
2007     Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for ischemic stroke
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2007     Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for medical inpatients
2012     Agency for Healthcare Research and Quality (AHRQ) Venous thromboembolism prophylaxis in orthopedic surgery
2007     National Institute for Health and Clinical Excellence (NICE) Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery
2001     Norwegian Knowledge Centre for the Health Services (NOKC) Ventilation in operating theatres
2013     New Zealand National Health Committee (NHC) Ventilation tubes: an opportunity for better targeting - technology note
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Ventilation/perfusion scintigraphy (using Technegas) versus computed tomography pulmonary angiography for the diagnosis of pulmonary embolism in hospitalized patients: a review of the clinical and cost-effectiveness
2005     HAYES, Inc. Ventricular assist devices
2003     HAYES, Inc. Ventricular assist devices
2010     HAYES, Inc. Ventricular Assist Devices (VADs) in children and adolescents with chronic, end-stage heart failure
1997     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Ventricular assistance devices as mechanical bridge to cardiac transplantation (internal report) IPE-97/f
2003     HAYES, Inc. Ventricular reduction surgery
2004     NIHR Health Technology Assessment programme VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers
2009     NIHR Health Technology Assessment programme VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers
2011     NIHR Health Technology Assessment programme VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers
2014     NIHR Health Technology Assessment programme VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model
2016     NIHR Horizon Scanning Centre (NIHR HSC) Vepoloxamer for vaso-occlusive crises in sickle cell disease – first line
2016     HAYES, Inc. Verasense (OrthoSensor Inc.) for use during total knee arthroplasty
2010     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Veress needle laparoscopic entry technique
2016     HAYES, Inc. VeriStrat
2014     HAYES, Inc. VeriStrat test to predict response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)
2012     HAYES, Inc. VeriStrat® Test to predict response to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)
2010     NIHR Horizon Scanning Centre (NIHR HSC) Vernakalant (IV) (Brinavess) for the treatment of recent onset atrial fibrillation
2011     HAYES, Inc. VersaJet hydrosurgery system (Smith&Nephew Inc.) for treatment of burns
2013     HAYES, Inc. VersaJet II hydrosurgery system (Smith & Nephew Inc.) for treatment of burns
2012     HAYES, Inc. VersaJet II hydrosurgery system (Smith & Nephew Inc.) for treatment of burns
2019     NIHR Health Technology Assessment programme Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT
2004     Blue Cross Blue Shield Association (BCBS) Vertebral assessment using dual-energy x-ray absorptiometry for osteoporotic fracture risk assessment
2007     Adelaide Health Technology Assessment (AHTA) Vertebral assessment with DEXA
2006     Adelaide Health Technology Assessment (AHTA) Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: a systematic review
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: an economic analysis
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: OHTAC recommendation
2005     WorkSafeBC Vertebral axial decompression for low back pain
2001     Medical Services Advisory Committee (MSAC) Vertebral axial decompression therapy for chronic low back pain
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Vertebroplasty